165 completed, 13 terminated, 6 unknown, 4 active not recruiting. 100 Phase 3, 59 Phase 2, 28 Phase 1, 9 Not applicable.
Follow NCIC Clinical Trials Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma Imetelstat - Neuroblastoma | Phase 1 | Withdrawn | NCIC Clinical Trials Group | 2013-07-30 | 2020-09-21 | |
| BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma BBI608, Placebo, Best Supportive Care - Colorectal Carcinoma | Phase 3 | Completed | NCIC Clinical Trials Group | 282 | 2013-05-10 | 2023-08-28 |
| Adjuvant PEG Intron in Ulcerated Melanoma PEG IFN alfa-2b - Ulcerated Melanomas | Phase 3 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 1200 | 2012-10-01 | 2019-03-04 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma AT7519M - Mantle Cell Lymphoma | Phase 2 | Completed | NCIC Clinical Trials Group | 12 | 2012-09-14 | 2023-08-04 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia AT7519M - Chronic Lymphocytic Leukemia | Phase 2 | Completed | NCIC Clinical Trials Group | 7 | 2012-08-27 | 2023-08-04 |
| A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma PF-03446962 - Malignant Pleural Mesothelioma | Phase 2 | Completed | NCIC Clinical Trials Group | 17 | 2012-06-26 | 2023-08-04 |
| A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer PX-866 - Prostate Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 68 | 2011-09-09 | 2023-08-22 |
| Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Dexamethasone, Placebo - Bone Metastases | Phase 3 | Completed | NCIC Clinical Trials Group | 298 | 2011-05-30 | 2023-08-28 |
| A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression PX-866 - Glioblastoma | Phase 2 | Completed | NCIC Clinical Trials Group | 34 | 2011-04-01 | 2023-08-22 |
| A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma AT9283 - Multiple Myeloma | Phase 2 | Completed | NCIC Clinical Trials Group | 8 | 2011-02-15 | 2023-08-04 |
| Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer Foretinib, Lapatinib - Breast Cancer | Phase 1 / Phase 2 | Completed | NCIC Clinical Trials Group | 19 | 2010-10-27 | 2023-08-04 |
| A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas SB939 - Metastatic Sarcoma | Phase 2 | Completed | NCIC Clinical Trials Group | 24 | 2010-10-21 | 2023-08-04 |
| A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia SB939 - Leukemia, Solid Tumours | Phase 1 | Completed | NCIC Clinical Trials Group | 12 | 2010-10-01 | 2023-08-04 |
| A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer Foretinib - Recurrent Breast Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 47 | 2010-09-02 | 2023-08-04 |
| Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma rIL-21, Dacarbazine - Melanoma | Phase 2 | Completed | NCIC Clinical Trials Group | 64 | 2010-08-05 | 2023-08-22 |
| SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer HDAC inhibitor SB939 - Prostate Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 32 | 2010-06-28 | 2023-08-04 |
| Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain methadone hydrochloride, questionnaire administration, management of therapy complications - Nausea and Vomiting, Pain | Phase 1 | Terminated | NCIC Clinical Trials Group | 8 | 2010-06-17 | 2024-02-12 |
| MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy MET/VEGFR2 inhibitor Foretinib, erlotinib hydrochloride, laboratory biomarker analysis - Lung Cancer | Phase 1 / Phase 2 | Completed | NCIC Clinical Trials Group | 31 | 2010-01-21 | 2023-08-04 |
| PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer PF-00299804, Placebo - Lung Cancer | Phase 3 | Completed | NCIC Clinical Trials Group | 720 | 2009-12-23 | 2023-08-22 |
| MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer anti-IGF-1R recombinant monoclonal antibody MK-0646, cisplatin, etoposide - Lung Cancer | Phase 1 / Phase 2 | Completed | NCIC Clinical Trials Group | 12 | 2009-12-16 | 2023-08-04 |
Showing 20 of 189. Sign in to see all of them.
Breast Neoplasms (33) · Lung Neoplasms (20) · Prostatic Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (19) · Lymphoma (14) · Colonic Neoplasms (13) · Colorectal Neoplasms (13) · Ovarian Neoplasms (11) · Rectal Neoplasms (11) · Carcinoma, Ovarian Epithelial (9) · Central Nervous System Neoplasms (9) · Endometrial Neoplasms (8) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Mantle-Cell (7) · Multiple Myeloma (7)
Radiotherapy (30) · Cisplatin (21) · Gemcitabine (15) · Docetaxel (13) · Doxorubicin (12) · Fluorouracil (12) · Paclitaxel (12) · Carboplatin (11) · Cyclophosphamide (10) · Leucovorin (9) · Prednisone (9) · Dexamethasone (8) · Chemotherapy, Adjuvant (7) · Etoposide (7) · Tamoxifen (7)
Canada (167) · United States (63) · United Kingdom (22) · Australia (19) · France (17) · Italy (17) · Belgium (16) · Netherlands (16) · Germany (12) · Spain (12) · Switzerland (12) · Poland (9) · Israel (8) · New Zealand (8) · Denmark (7)
Paul E. Goss, MD, PhD (8) · James N. Ingle, MD (6) · Kim N. Chi, MD (6) · Malcolm J. Moore, MD (6) · Laurence H. Klotz, MD (5) · Karen A. Gelmon, MD (4) · Lillian L. Siu, MD, FRCPC (4) · Michael R. Crump, MD, FRCPC (4) · Scott A. Laurie, MD, FRCPC (4) · Timothy J. Whelan, MD (4) · Amit M. Oza, MD (3) · Eric X. Chen, MD, PhD (3) · Gerald Batist, MD (3) · Jennifer Knox, MD (3) · Kathy S. Albain, MD (3)
PMID 18398152, PMID 27750483, PMID 28379421, PMID 30466310, PMID 33270906, PMID 33853037, PMID 40215447, PMID 11241082, PMID 11586105, PMID 11790211, PMID 12377323, PMID 12431965, PMID 12636887, PMID 12694666, PMID 12702532, PMID 12735303, PMID 12837810, PMID 12947070, PMID 14551341, PMID 14586216, PMID 14630682, PMID 14656276, PMID 14665611, PMID 15033677, PMID 15102658, PMID 15122073, PMID 15122079, PMID 15141043, PMID 15197210, PMID 15251162, PMID 15304161, PMID 15386331, PMID 15470715, PMID 15623591, PMID 15659491, PMID 15677624, PMID 15699482, PMID 15713522, PMID 15758009, PMID 15758010, PMID 15837968, PMID 15837997, PMID 15839957, PMID 15972865, PMID 16034522, PMID 16034524, PMID 16135479, PMID 16145047, PMID 16145049, PMID 16157934
U10CA032102 (11), U10CA031946 (6), U10CA021115 (4), 2004 (3), U10CA180820 (3), 2005 (2), U10CA023318 (2), U10CA025224 (2), U10CA180821 (2), 2009 (1), N01CM17003 (1), N02CM62212 (1), U10CA027469 (1), U10CA037429 (1), U10CA077202 (1)